| |  Online-Ressource |
|---|
| Verfasst von: | Lodde, Georg Christian [VerfasserIn]  |
|---|
| | Zhao, Fang [VerfasserIn] |
|---|
| | Herbst, Rudolf [VerfasserIn] |
|---|
| | Terheyden, Patrick [VerfasserIn] |
|---|
| | Utikal, Jochen [VerfasserIn] |
|---|
| | Pföhler, Claudia [VerfasserIn] |
|---|
| | Ulrich, Jens [VerfasserIn] |
|---|
| | Kreuter, Alexander [VerfasserIn] |
|---|
| | Mohr, Peter [VerfasserIn] |
|---|
| | Gutzmer, Ralf [VerfasserIn] |
|---|
| | Meier, Friedegund [VerfasserIn] |
|---|
| | Dippel, Edgar [VerfasserIn] |
|---|
| | Weichenthal, Michael [VerfasserIn] |
|---|
| | Jansen, Philipp [VerfasserIn] |
|---|
| | Kowall, Bernd [VerfasserIn] |
|---|
| | Galetzka, Wolfgang [VerfasserIn] |
|---|
| | Hörst, Fabian [VerfasserIn] |
|---|
| | Kleesiek, Jens Philipp [VerfasserIn] |
|---|
| | Hellwig, Birte [VerfasserIn] |
|---|
| | Rahnenführer, Jörg [VerfasserIn] |
|---|
| | Rajcsanyi, Luisa [VerfasserIn] |
|---|
| | Peters, Triinu [VerfasserIn] |
|---|
| | Hinney, Anke [VerfasserIn] |
|---|
| | Placke, Jan-Malte [VerfasserIn] |
|---|
| | Sucker, Antje [VerfasserIn] |
|---|
| | Paschen, Annette [VerfasserIn] |
|---|
| | Becker, Jürgen C. [VerfasserIn] |
|---|
| | Livingstone, Elisabeth [VerfasserIn] |
|---|
| | Zimmer, Lisa [VerfasserIn] |
|---|
| | Tasdogan, Alpaslan [VerfasserIn] |
|---|
| | Roesch, Alexander [VerfasserIn] |
|---|
| | Hadaschik, Eva [VerfasserIn] |
|---|
| | Schadendorf, Dirk [VerfasserIn] |
|---|
| | Griewank, Klaus [VerfasserIn] |
|---|
| | Ugurel, Selma [VerfasserIn] |
|---|
| Titel: | Early versus late response to PD-1-based immunotherapy in metastatic melanoma |
|---|
| Verf.angabe: | Georg C. Lodde, Fang Zhao, Rudolf Herbst, Patrick Terheyden, Jochen Utikal, Claudia Pföhler, Jens Ulrich, Alexander Kreuter, Peter Mohr, Ralf Gutzmer, Friedegund Meier, Edgar Dippel, Michael Weichenthal, Philipp Jansen, Bernd Kowall, Wolfgang Galetzka, Fabian Hörst, Jens Kleesiek, Birte Hellwig, Jörg Rahnenführer, Luisa Rajcsanyi, Triinu Peters, Anke Hinney, Jan-Malte Placke, Antje Sucker, Annette Paschen, Jürgen C. Becker, Elisabeth Livingstone, Lisa Zimmer, Alpaslan Tasdogan, Alexander Roesch, Eva Hadaschik, Dirk Schadendorf, Klaus Griewank, Selma Ugurel |
|---|
| E-Jahr: | 2024 |
|---|
| Jahr: | October 2024 |
|---|
| Umfang: | 10 S. |
|---|
| Fussnoten: | Online verfügbar: 23. August 2024, Artikelversion: 29. August 2024 ; Gesehen am 20.11.2024 |
|---|
| Titel Quelle: | Enthalten in: European journal of cancer |
|---|
| Ort Quelle: | Amsterdam [u.a.] : Elsevier, 1992 |
|---|
| Jahr Quelle: | 2024 |
|---|
| Band/Heft Quelle: | 210(2024), Artikel-ID 114295, Seite 1-10 |
|---|
| ISSN Quelle: | 1879-0852 |
|---|
| Abstract: | Background - Immune checkpoint inhibition (ICI) currently is the most effective treatment to induce durable responses in metastatic melanoma. The aims of this study are the characterization of patients with early, late and non-response to ICI and analysis of survival outcomes in a real-world patient cohort. - Methods - Patients who received PD-1-based immunotherapy for non-resectable stage-IV melanoma in any therapy line were selected from the prospective multicenter real-world DeCOG study ADOREG-TRIM (NCT05750511). Patients showing complete (CR) or partial (PR) response already during the first 3 months of treatment (Early Responders, EarlyR) were compared to patients showing CR/PR at a later time (Late Responders, LateR), a stable disease (SD) and to patients showing progressive disease (Non-Responders, NonR). - Results - Of 522 patients, 8.2 % were EarlyR (n = 43), 19.0 % were LateR (n = 99), 37.0 % had a SD (n = 193) and 35.8 % were NonR (n = 187). EarlyR, LateR and SD patients had comparable baseline characteristics. Multivariate logbinomial regression analyses adjusted for age and sex revealed positive tumor PD-L1 (RR=1.99, 95 %-CI=1.14-3.46, p = 0.015), and normal serum CRP (RR=1.59, 95 %-CI=0.93-2.70, p = 0.036) as independently associated with the achievement of an early response compared to NonR. The median progression-free and overall survival was 46.0 months (95 % CI 19.1; NR) and 47.8 months (95 %-CI 36.9; NR) for EarlyR, NR (95 %-CI NR; NR) for LateR, 8.1 months (7.0; 10.4) and 35.4 months (29.2; NR) for SD, and 2.0 months (95 %-CI 1.9; 2.1) and 6.1 months (95 %-CI 4.6; 8.8) for NonR patients. - Conclusion - Less than 10 % of metastatic melanoma patients achieved an early response during the first 3 months of PD-1-based immunotherapy. Early responders were not superior to late responders in terms of response durability and survival. |
|---|
| DOI: | doi:10.1016/j.ejca.2024.114295 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
kostenfrei: Volltext: https://doi.org/10.1016/j.ejca.2024.114295 |
|---|
| | kostenfrei: Volltext: https://www.sciencedirect.com/science/article/pii/S0959804924009511 |
|---|
| | DOI: https://doi.org/10.1016/j.ejca.2024.114295 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | Best overall response |
|---|
| | CTLA-4 |
|---|
| | Immune checkpoint inhibition |
|---|
| | Immunotherapy |
|---|
| | Melanoma |
|---|
| | PD-1 |
|---|
| | PD-L1 |
|---|
| | Survival |
|---|
| | Therapy outcome |
|---|
| K10plus-PPN: | 1909083046 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Early versus late response to PD-1-based immunotherapy in metastatic melanoma / Lodde, Georg Christian [VerfasserIn]; October 2024 (Online-Ressource)
